Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Bioorg Med Chem Lett. 2013 Jul 2;23(17):10.1016/j.bmcl.2013.06.065. doi: 10.1016/j.bmcl.2013.06.065

Table 1. Binding affinities and functional activities of bifunctional peptide derivatives at δ/μ opioid receptors and NK1 receptors.

Opioid agonist activities NK1 antagonist activities

radioligand binding assays [35S] GTPγS binding assays MVD (δ) GPI (μ) radioligand binding assays GPI

hDORa,b rMORa,c Ki(μ)
/Ki(δ)
hDORa rMORa Opioid agonist hNK1d,e rNK1d,f Ki(hNK1)
/Ki(rNK1)
Substance P antagonist



no Ki
(nM)g
Ki
(nM)g
EC50
(nM)h
Emax
(%)i
EC50
(nM)h
Emax
(%)i
IC50
(nM)j
IC50
(nM)j
Ki
(nM)g
Ki
(nM)g
Ke
(nM)k
1l 2.8 36 13 2.9 45 32 42 22 360 0.082 0.29 3.5 25
2 25 150 6.0 2.5 26 72 51 12 1200 0.034 1.1 32 380
3 5.0 110 22 0.26 41 54 52 5.1 6.8%@1μM 0.066 7.8 118 2.0
4 3.1 63 20 5.5 28 100 27 6.9 42%@1μM 0.12 9.8 82 12
5 13 76 5.8 190 25 120 30 8.5 25%@1μM 0.88 3.6 4.1 29
6m 50 180 3.6 35 16 140 26 400 520 0.0023 1.6 696 3.6
7 2.9 23 7.9 4.8 60 14 54 26 45 0.09 0.29 3.2 Not tested
8 0.6 33 55 1.1 36 0.80 51 9.1 390 0.0090 0.089 9.9 2.0
9 5.7 15 2.6 76 56 37 47 85 260 0.097 1.6 16 1.8
10 4.7 0.29 0.062 27 87 10 36 21 26 0.0057 4.2 737 59
Biphalinn 2.6 1.4 0.54 1.1 83 2.7 8.8
DAMGO 37 150
L-732,138 0.73 130 180 250
a

Competition analyses were carried out using membrane preparations from transfected HN9.10 cells that constitutively expressed the DOR and MOR. See reference 3 for detailed procedures.

b

[3H]DPDPE; Kd = 0.45 ± 0.1 nM.

c

[3H]DAMGO; Kd = 0.50 ± 0.1 nM.

d

Competition analyses were carried out using membrane preparations from transfected CHO cells that constitutively expressed rat or human NK1 receptors. See reference 3 for detailed procedures.

e

[3H]Substance P; Kd = 0.16 ± 0.03 nM.

f

[3H] Substance P; Kd = 0.40 ± 0.17 nM.

g

The data were collected from at least two independent experiments performed in duplicate. The Ki values are calculated using the Cheng and Prusoff equation to correct for the concentration of the radioligand used in the assay. See reference 3 for detailed procedures.

h

The EC50 values were determined from the non-linear regression analysis of data collected from at least two independent experiments performed in duplicate. See reference 3 for detailed procedures.

i

[Total bound − Basal]/[Basal − Non-specific] × 100.

j

Concentration at 50% inhibition of muscle contraction at electrically stimulated isolated tissues (n = 4).

k

Inhibitory activity against the Substance P induced muscle contraction in the presence of 1 μM naloxone, Ke: concentration of antagonist needed to inhibit Substance P to half its activity (n = 4). See reference 3 for detailed procedures.